Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5508 and/or QLH12016 in Advanced Prostate Cancer
NCT07198633Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Bivalent/Multivalent Binders, Antibody-Drug Conjugates (ADCs), PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of MHB088C, QLH12016 in prostate cancer (PCa), sponsored by Qilu Pharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
MHB088CQLH12016
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07198633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198633.